California-based NuEyes has secured approval from the US Food and Drug Administration (FDA) for its patent-pending augmented reality loupes NuLoupes.

According to the augmented reality smart glasses technology provider, the NuLoupes device features 3D stereoscopic technology to offer a high level of precision and live 3D visualisation for dentistry and medicine practitioners.

NuEyes founder and CEO Mark Greget said: “We are thrilled to announce the FDA approval of NuLoupes, a testament to our commitment to innovation and excellence in the medical technology field.

“NuLoupes represents a huge leap forward in visualisation technology, and we are confident that they will revolutionise the way medical professionals approach their work.”

NuEyes claimed that NuLoupes with its high-resolution variable digital magnification offers surgeons and dentists increased versatility and a broader viewing area.

By leveraging NuEyes’ proprietary patent-pending camera system, NuLoupes delivers live 3D stereoscopic imaging with near-zero latency. This helps in providing sub-millimetre accurate depth perception for a precise understanding of the observed environment, said the company.

The company indicated that the technology is instrumental in delivering a natural viewing experience with enhanced magnification for detailed tasks.

NuLoupes is said to be the first smart glasses featuring live 3D stereoscopic imaging to have received FDA clearance.

For a limited time, NuEyes will offer an exclusive quantity of NuLoupes developer kits to software developers, clinicians working on medical applications, or early adopters wanting to access NuLoupes before its official market release.

The NuLoupes developer kit includes a comprehensive software development kit (SDK) that will grant exclusive access to the device’s 3D stereoscopic camera sensors, infrared (IR) sensor, inertial measurement unit (IMU), Android operating system, Unity plug-ins, with additional features to be revealed soon.

The developer kits are anticipated to be shipped in Q1 2024, said the company.